Download MendeleyJDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS G12C for the Treatment of Solid Tumors.
Lorthiois, E., Gerspacher, M., Beyer, K.S., Vaupel, A., Leblanc, C., Stringer, R., Weiss, A., Wilcken, R., Guthy, D.A., Lingel, A., Bomio-Confaglia, C., Machauer, R., Rigollier, P., Ottl, J., Arz, D., Bernet, P., Desjonqueres, G., Dussauge, S., Kazic-Legueux, M., Lozac'h, M.A., Mura, C., Sorge, M., Todorov, M., Warin, N., Zink, F., Voshol, H., Zecri, F.J., Sedrani, R.C., Ostermann, N., Brachmann, S.M., Cotesta, S.(2022) J Med Chem 65: 16173-16203
- PubMed: 36399068
- DOI: https://doi.org/10.1021/acs.jmedchem.2c01438
- Primary Citation of Related Structures:
8AQ5, 8AQ7 - PubMed Abstract:
Rapid emergence of tumor resistance via RAS pathway reactivation has been reported from clinical studies of covalent KRAS G12C inhibitors. Thus, inhibitors with broad potential for combination treatment and distinct binding modes to overcome resistance mutations may prove beneficial. JDQ443 is an investigational covalent KRAS G12C inhibitor derived from structure-based drug design followed by extensive optimization of two dissimilar prototypes. JDQ443 is a stable atropisomer containing a unique 5-methylpyrazole core and a spiro-azetidine linker designed to position the electrophilic acrylamide for optimal engagement with KRAS G12C C12. A substituted indazole at pyrazole position 3 results in novel interactions with the binding pocket that do not involve residue H95. JDQ443 showed PK/PD activity in vivo and dose-dependent antitumor activity in mouse xenograft models. JDQ443 is now in clinical development, with encouraging early phase data reported from an ongoing Phase Ib/II clinical trial (NCT04699188).
Organizational Affiliation:
Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland.
